Medicines
SmPC of 04/03/2020
LAVOISIER WATER FOR INJECTABLE PREPARATIONS, solution for injectable preparation
Composition
Water for injectable preparations ..................................................................................................... q.s.
For one vial or one ampoule.
None.
Indications
Extemporaneous dilution or dissolution of preparations intended for parenteral administration.
Dosage and administration
Dosage
The posology depends on the specialties dissolved in water for injectable preparations.
Method of administration
The mode of administration depends on the specialties dissolved in water for injectable preparations.
Warnings and precautions
Special warnings
As water for injection preparations is a hypotonic solution, intended for the preparation of solutions for parenteral administration, it must not be injected alone.
Precautions for use
The mixture must be prepared extemporaneously with sterile equipment and under strict aseptic conditions.
Before use, check that the solution is clear.
For vials: before use, check the integrity of the closure and disinfect the stopper.
Interactions
Before dissolving a medicinal product, check its solubility and/or stability in water.
In the case of a mixture of several active substances, check their compatibility with one another.
Fertility, pregnancy and breastfeeding
Pregnancy
The risks during use in pregnant women are determined by the nature of the pharmaceutical specialties added.
Breast-feeding
The risks during use in breastfeeding women are determined by the nature of the pharmaceutical specialties added.
Driving and using machines
The effects on the ability to drive vehicles and use machines are linked to the medicinal product(s) to be dissolved or diluted: refer to the leaflet accompanying each medicinal product to be added.
Adverse effects
Intravenous injection of water for injection preparations may cause haemolysis if administered alone.
The nature of the additive will determine the possible occurrence of other undesirable effects.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres - Website:www.signalement-sante.gouv.fr.
Overdose
Haemolysis may occur after infusion of large quantities of hypotonic solutions with water for injection preparations as diluent.
The signs and symptoms of overdose will also be linked to the nature of the added medicinal products.
In case of accidental overdose, treatment must be interrupted and the patient must be monitored for signs and symptoms related to the medicinal products administered.
Preclinical safety
Since water for injections is only a vehicle for the administration of one or more additive pharmaceutical specialties, the preclinical safety data for the solution to be used will depend on the nature of the additive medicinal product.
INCOMPATIBILITIES
Certain medicinal products may be incompatible. Medicinal products known to be incompatible must not be used.
Before adding any medicinal products, check:
- whether they are soluble in water for injections,
- whether they are stable at the pH of water for injections,
- whether they are compatible with each other.
Shelf life
Before opening:
3 years.
Shelf life after first use:
After opening/dilution, the product must be used immediately.
Special storage precautions
This medicinal product does not require any special storage precautions before opening.
For storage conditions of the medicine after opening, see section Shelf life.
SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING
No special requirements for disposal.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Prescription, supply and reimbursement
| Marketing authorisation (AMM) |
|
Hospital model(s) (6Fl/1000ml, 12Fl/200-250ml, 24Fl/50-125ml, 24Fl/100-125ml, 10Fl/500ml, 10Fl/1000ml, 100AmpPP/5ml, 100AmpPP/10ml, 50Amp/20ml).
Collect (6Fl/1000ml, Fl/500ml, Fl/250ml, 24Fl/50-125ml, 24Fl/100-125ml, 10Amp/5ml, 10Amp/10ml, 10Amp/20ml, 10Fl/500ml, 10Fl/1000ml, 10AmpPP/10ml, 10AmpPP/20ml, 100AmpPP/5ml, 100AmpPP/10ml, 50Amp/20ml).
7 RUE PASQUIER
75008 PARIS
Tel: 01 55 37 83 83 commercial@lavoisier.com
https://www.lavoisier.com/fr/
Source: VIDAL · Updated on 11/11/2026. This information does not replace advice from a healthcare professional.
